# Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Source: https://onco.cc/trials/nct04150497/  
OnCo record `nct04150497` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of UCART22 in acute lymphoblastic leukaemia, run by Cellectis S.A., now recruiting.

## Summary

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) is a phase 1/2 interventional study registered as NCT04150497 by Cellectis S.A., with 52 participants planned, started 2019-10-14 and due to reach its primary completion in 2026-06-30. Interventions recorded: UCART22 and CLLS52.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04150497
- Phase: 1/2
- Setting: Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Sponsor: Cellectis S.A.
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT04150497: https://clinicaltrials.gov/study/NCT04150497

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [UCART22](https://onco.cc/drugs/ucart22/)
- companies: [Cellectis S.A.](https://onco.cc/companies/cellectis-s-a/)

---
JSON: https://onco.cc/api/v1/entities/nct04150497.json